Regeneron Pharmaceuticals, Inc. (ETR:RGO)
Germany · Delayed Price · Currency is EUR | Market Cap | 69.30B +39.7% |
| Revenue (ttm) | 13.60B +9.3% |
| Net Income | 3.79B -2.9% |
| EPS | 35.39 +1.9% |
| Shares Out | n/a |
| PE Ratio | 18.29 |
| Forward PE | 12.07 |
| Dividend | 3.25 (0.47%) |
| Ex-Dividend Date | May 20, 2026 |
| Volume | n/a |
| Open | 685.00 |
| Previous Close | 693.60 |
| Day's Range | 685.00 - 685.00 |
| 52-Week Range | 464.70 - 702.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg
BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #biosimilar--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg, Used to Treat Various Types of Ophth...
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 ...
Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue grew 17% year-over-year to $4.3B, with double-digit EPS growth and record sales for Dupixent, EYLEA HD, and Libtayo. Pipeline advances and upcoming regulatory milestones support a strong outlook, while robust cash flow enables continued R&D and shareholder returns.
Regeneron Pharmaceuticals Earnings release: Q2 2026
Regeneron Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Regeneron Pharmaceuticals Quarterly report: Q2 2026
Regeneron Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Regeneron Pharmaceuticals Slides: Q2 2026
Regeneron Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Regeneron beats quarterly estimates on eczema drug strength, shares rise
Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea.
Regeneron Reports Second Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update.
REGN Stockholders Have Rights – If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceut...
The Scientist With 1,000 Patents Fueling a Drug Powerhouse
At Regeneron, George Yancopoulos is the rare scientist and executive who drives growth with discoveries instead of acquisitions.
$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FD...
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $REGN #BFA--Regeneron Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA.
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings
Booking Holdings, Alphabet, and six other companies have underperformed their sectors despite improving earnings expectations, setting up potential upside during second-quarter earnings season.
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing fa...
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck...
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursda...
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing
Regeneron Pharmaceuticals Transcript: AGM 2026
The meeting approved all board proposals, including director elections, auditor ratification, and executive compensation. Strong financial growth was reported, with significant R&D investment and pipeline expansion highlighted. No shareholder questions were submitted.
Regeneron Pharmaceuticals Slides: FY 2026
Regeneron Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 12, 2026.
Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Strong Q1 growth was driven by core franchises, with EYLEA HD and DUPIXENT showing momentum. The pipeline remains robust, with key catalysts expected in the second half, including regulatory and clinical milestones. Strategic flexibility in M&A and collaborations, plus a focus on IP protection and next-generation assets, position the company for long-term growth.
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare...
Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically ...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The investigation c...